Stock Fundamentals

Company Information

Company Name
Werewolf Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US95075A1079
CIK: 0001785530
CUSIP: 95075A107
Currency: USD
Full Time Employees: 39
Phone: 617 952 0555
Fiscal Year End: December
IPO Date: Apr 30, 2021
Description:

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Address:

200 Talcott Ave, Watertown, MA, United States, 02472

Directors & Officers

Name Title Year Born
Dr. Daniel J. Hicklin Ph.D. Founder, CEO, President, Secretary & Director 1964
Mr. Michael Urban VP of Finance, Corporate Controller, Principal Financial Officer & Principal Accounting Officer 1981
Mr. Steven H. Bloom R.Ph. Chief Business Officer 1961

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 16, 2026 Luke Evnin N/A Sale 38.78K $0.54 $20.94K
Jan 15, 2026 Luke Evnin N/A Sale 37.41K $0.55 $20.58K
Jan 14, 2026 Luke Evnin N/A Sale 30.62K $0.57 $17.45K
Jan 13, 2026 Luke Evnin N/A Sale 43.20K $0.55 $23.76K
Jan 12, 2026 Luke Evnin N/A Sale 58.98K $0.57 $33.62K
Jan 09, 2026 Luke Evnin N/A Sale 24.68K $0.61 $15.05K
Jan 08, 2026 Luke Evnin N/A Sale 7.72K $0.63 $4.86K
Jan 07, 2026 Luke Evnin N/A Sale 11.92K $0.64 $7.63K
Jan 06, 2026 Luke Evnin N/A Sale 40.76K $0.65 $26.49K
Jan 05, 2026 Luke Evnin N/A Sale 18.38K $0.64 $11.76K
Jan 02, 2026 Luke Evnin N/A Sale 18.57K $0.63 $11.70K
Dec 31, 2025 Luke Evnin N/A Sale 24.96K $0.62 $15.48K
Dec 30, 2025 Luke Evnin N/A Sale 34.85K $0.61 $21.26K
Dec 29, 2025 Luke Evnin N/A Sale 108.61K $0.61 $66.25K
Dec 26, 2025 Luke Evnin N/A Sale 35.63K $0.63 $22.45K
Dec 24, 2025 Luke Evnin N/A Sale 16.31K $0.65 $10.60K
Dec 23, 2025 Luke Evnin N/A Sale 71.43K $0.63 $45.00K
Dec 22, 2025 Luke Evnin N/A Sale 59.31K $0.69 $40.92K
Dec 17, 2025 Luke Evnin N/A Sale 9.98K $1.14 $11.38K
Dec 16, 2025 Luke Evnin N/A Sale 14.55K $1.05 $15.28K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 6.68M Mar 31, 2026 13.75% $0.06 0.00%
Vanguard Group Inc 1.41M Dec 31, 2025 2.90% $0.00 0.00%
MPM Oncology Impact Management LP 1.21M Mar 31, 2026 2.49% $0.08 -13.26%
Lynx1 Capital Management, LP 657.79K Mar 31, 2026 1.35% $0.09 0.28%
Sphera Funds Management Ltd. 626.81K Mar 31, 2026 1.29% $0.08 0.00%
DC Funds, LP 589.10K Mar 31, 2026 1.21% $33.01 0.00%
Squadron Capital Management LLC 563.54K Mar 31, 2026 1.16% $0.17 0.00%
Renaissance Technologies Corp 516.22K Mar 31, 2026 1.06% $0.00 -23.84%
Geode Capital Management, LLC 389.49K Mar 31, 2026 0.80% $0.00 15.96%
Bank of America Corp 264.58K Mar 31, 2026 0.54% $0.00 -64.13%
Millennium Management LLC 132.05K Mar 31, 2026 0.27% $0.00 -45.00%
State Street Corp 119.17K Mar 31, 2026 0.25% $0.00 0.00%
BlackRock Inc 101.61K Mar 31, 2026 0.21% $0.00 -0.03%
Northern Trust Corp 86.85K Mar 31, 2026 0.18% $0.00 0.00%
Alyeska Investment Group, L.P. 86.55K Mar 31, 2026 0.18% $0.00 -63.28%
Jane Street Group LLC 82.84K Mar 31, 2026 0.17% $0.00 -47.35%
Bridgeway Capital Management, LLC 77.00K Mar 31, 2026 0.16% $0.00 0.00%
UBS Group AG 66.86K Mar 31, 2026 0.14% $0.00 10.13%
XTX Topco Ltd 50.93K Mar 31, 2026 0.10% $0.00 0.00%
The Goldman Sachs Group Inc 38.27K Mar 31, 2026 0.08% $0.00 12.31%

Shares Statistics

Shares Outstanding: 48.60M
Shares Float: 41.23M
% Insiders: 561.50%
% Institutions: 3,521.30%
Short % Float: 1.66%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 873.75K 1.80% ▲ 0.00% Apr 30, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 344.23K 0.71% ▲ 0.00% Apr 30, 2026
3 Vifag 2002 SICAV 220.00K 0.45% ▲ 0.00% Feb 28, 2026
4 Fidelity Extended Market Index 218.27K 0.45% ▲ 30.60% Mar 31, 2026
5 Abante Quant Value FI 117.32K 0.24% ▲ 33.55% Mar 31, 2026
6 Bridgeway Ultra-Small Company Market 75.00K 0.15% ▲ 0.00% Mar 31, 2026
7 Blackrock Extended Mkt Fund CF 64.85K 0.13% ▲ 0.00% Apr 30, 2026
8 Extended Equity Market Fund E 64.85K 0.13% ▲ 0.00% Dec 31, 2025
9 Extended Equity Market Fund B 64.85K 0.13% ▲ 0.00% Dec 31, 2025
10 NT Ext Equity Mkt Index Fund - Lending 60.65K 0.12% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $14.17M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $20.90M
EBITDA: $-54.35M
Book Value: $0.25
Earnings/Share: $-1.21
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -42.33%
ROE (TTM): -161.89%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.62x 0.07x 0.64x -11.50x -0.03x
2024-12-31 7.45x 0.38x 0.42x -15.81x -0.43x
2023-12-31 7.14x 0.37x 0.36x -12.90x -1.26x
2022-12-31 5.84x 0.02x 0.24x -50.78x -0.04x
2021-12-31 13.56x 0.01x 0.15x -231.88x -0.02x
2020-12-31 17.58x 0.01x 0.07x -221.82x -0.05x
2019-12-31 8.84x 0.06x 0.55x -26.71x -0.06x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about HOWL.US!